Table 1.
Demographic and clinical characteristics of patients.
| Gefitinib (n = 116) | Erlotinib (n = 75) | Afatinib (n = 115) | p value | |
|---|---|---|---|---|
| Age, n (%) | 0.16 | |||
| ≥60 | 92 (79.3%) | 59 (78.7%) | 80 (69.6%) | |
| <60 | 24 (20.7%) | 16 (21.3%) | 35 (30.4%) | |
| Sex, n (%) | 0.63 | |||
| Male | 43 (37.1%) | 33 (44.0%) | 45 (39.1%) | |
| Female | 73 (62.9%) | 42 (56.0%) | 70 (60.9%) | |
| Smoking, n (%) | 0.38 | |||
| Positive | 90 (77.6%) | 57 (76.0%) | 96 (83.5%) | |
| Negative | 26 (22.4%) | 18 (24.0%) | 19 (16.5%) | |
| Tumor size, n (%) | 0.68 | |||
| ≥3 cm | 23 (19.8%) | 14 (18.7%) | 24 (20.9%) | |
| <3 cm | 80 (69.0%) | 51 (68.0%) | 83 (72.2%) | |
| NA | 13 (11.2%) | 10 (13.3%) | 8 (6.9%) | |
| Nodal involvement, n (%) | 0.85 | |||
| N0 | 17 (14.7%) | 13 (17.3%) | 19 (16.5%) | |
| N1/N2/N3 | 99 (85.3%) | 62 (82.7%) | 96 (83.5%) | |
| Stage, n (%) | 0.44 | |||
| Recurrence | 19 (16.4%) | 7 (9.3%) | 17 (14.8%) | |
| Stage IIIB | 91 (79.4%) | 67 (89.3%) | 96 (82.5%) | |
| Stage IV | 5 (4.2%) | 1 (1.4%) | 3 (2.7%) | |
| ECOG PS, n (%) | 0.01 | |||
| 0–1 | 99 (85.3%) | 58 (77.3%) | 102 (88.7%) | |
| ≥2 | 14 (12.1%) | 17 (22.7%) | 9 (7.8%) | |
| NA | 3 (2.6%) | 0 | 4 (3.5%) | |
| EGFR mutation, n (%) | <0.001 | |||
| Del 19 | 32 (27.6%) | 26 (34.7%) | 70 (60.9%) | |
| L858R | 76 (65.5%) | 45 (60.0%) | 28 (24.3%) | |
| Others | 6 (5.2%) | 3 (4.0%) | 11 (9.6%) | |
| Multiple | 2 (1.7%) | 1 (1.3%) | 6 (5.2%) | |
| Initial BM, n (%) | 23 (19.8%) | 34 (45.3%) | 30 (26.1%) | <0.001 |
BM, brain metastases; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; PS, performance status; NA, not applicable.